
    
      This study was a multi-center, open-label, single-sequence, crossover study to evaluate the
      pharmacokinetics (PK), safety and tolerability of SC-administered GAMUNEX-C in pediatric PI
      subjects (ages 2-16). The study consisted of a Screening Phase, Run-in Phase, two treatment
      phases (an IV Phase and a SC Phase), and an End of Study/Early Termination (EOS/ET) visit.
      Run-in phase: 3 - 4 months, IV Phase: ~ 4 - 5 weeks, SC Phase: 12 weeks, and End of
      Study/Early Termination (EOS/ET) visit: one week after SC Week #12.
    
  